Khiron (TSXV: KHRN) announces appointment of Medical Director
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) announced the appointment of Dr. Edwin Bendek, MD, MA, MPH as Medical Director, Skincare. Dr. Bendek is a recognized pioneer in CBD cosmeceutical product innovation who brings 20 years of global experience in general dermatology, cutaneous surgery, anti-aging dermatology and predictive genetics. He is a graduate of Medical Dermatology from Universidad Javeriana, Colombia, specialist in anti-aging from the WOSIAM in Paris, Master in Public Health from the Universidad de Granada, Master in Bioethics, Health and Law from the Université de Rennes and Specialist in clinical trials from Harvard University. The addition of Dr. Bendek to an already impressive management team confirms KHRN’s commitment to the cosmeceutical space.
Andres Galofre, Khiron Co-founder and VP Business Development, said, "Dr. Bendek's proven skincare and cosmetology experience, together with his exceptional industry network will be invaluable as we execute our research-based, product development strategy."
On a slightly different note, when I was a fledgling analyst many years ago, a company I was following made a blockbuster announcement. As I had recently spoken to management, I was annoyed that the President hadn’t given me a head’s up that something was in the works. So I called him on it and he said, “Well, I did give you a pretty strong hint when I said….” I realized I hadn’t been listening. I try to never make the same mistake twice. So when I was watching KHRN President Chris Naprawa being interviewed, I made a note when he said and I’m paraphrasing: “Brazil, with 240 million people, has the potential to be the leading medical market in the world. We’ll have more news coming.” There you have it. Don’t make the same mistake I did all those years ago. See the Chris Naprawa interview (here).